Free Trial
NASDAQ:CABA

Cabaletta Bio (CABA) Stock Price, News & Analysis

Cabaletta Bio logo
$1.69 -0.05 (-2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$1.71 +0.02 (+1.18%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cabaletta Bio Stock (NASDAQ:CABA)

Key Stats

Today's Range
$1.65
$1.77
50-Day Range
$1.15
$2.48
52-Week Range
$0.99
$8.44
Volume
1.26 million shs
Average Volume
1.69 million shs
Market Capitalization
$85.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.43
Consensus Rating
Buy

Company Overview

Cabaletta Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

CABA MarketRank™: 

Cabaletta Bio scored higher than 53% of companies evaluated by MarketBeat, and ranked 539th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cabaletta Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Cabaletta Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($2.34) to ($2.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cabaletta Bio is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cabaletta Bio is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cabaletta Bio has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Cabaletta Bio's valuation and earnings.
  • Percentage of Shares Shorted

    12.46% of the float of Cabaletta Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 13.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cabaletta Bio does not currently pay a dividend.

  • Dividend Growth

    Cabaletta Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.46% of the float of Cabaletta Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Cabaletta Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cabaletta Bio has recently decreased by 13.29%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cabaletta Bio has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cabaletta Bio this week, compared to 3 articles on an average week.
  • Search Interest

    Only 6 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
  • MarketBeat Follows

    Only 17 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cabaletta Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.25% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Cabaletta Bio's insider trading history.
Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

CABA Stock News Headlines

Cabaletta Bio Inc News (CABA) - Investing.com
Cabaletta Bio, Inc. (CABA) - Yahoo Finance
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
See More Headlines

CABA Stock Analysis - Frequently Asked Questions

Cabaletta Bio's stock was trading at $2.27 at the beginning of 2025. Since then, CABA shares have decreased by 25.6% and is now trading at $1.69.

Cabaletta Bio, Inc. (NASDAQ:CABA) posted its earnings results on Wednesday, May, 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.04.

Cabaletta Bio (CABA) raised $87 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 5,800,000 shares at $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cabaletta Bio investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

Last Earnings
5/21/2025
Today
7/14/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CABA
CIK
1759138
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$3.00
Potential Upside/Downside
+753.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$115.86 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-78.29%
Return on Assets
-65.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.96
Quick Ratio
3.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.12 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
50,740,000
Free Float
45,034,000
Market Cap
$85.75 million
Optionable
Optionable
Beta
2.70
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:CABA) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners